CPX-351 for high-risk MDS or CMML that came back
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This Phase 1 trial studies CPX-351, a cancer medicine, in people with high-risk myelodysplastic syndrome (MDS) or chronic myelomonocytic leukemia (CMML) whose disease relapsed or did not respond to prior treatment. It may help shrink or control the leukemia and improve blood counts in patients who cannot or do not want a stem cell transplant.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have MDS or CMML confirmed by accepted diagnostic criteria
- You cannot or choose not to get a stem cell transplant right now
- Your disease is high risk (intermediate-2/high risk) with higher-than-normal blast cells in the marrow
- Your disease did not respond after at least 4 treatment cycles, or it returned or worsened after prior medicines like azacitidine, decitabine, guadecitabine, or oral decitabine (ASTX727)
- Your liver and kidney tests are within limits (bilirubin under 3 mg/dL, AST/ALT no more than 3x normal, kidney filtration above 30)
- You agree to the study by signing informed consent
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase study tests a new drug called STX-0712 for people with certain types of blood cancers (CMML or AML) that have not responded to standard treatments. The goal is to see if the drug is safe and can help shrink or control the cancer.
This trial tests a strong chemotherapy and radiation combo followed by a donor stem cell transplant for people with aggressive blood cancers (like AML or MDS) that haven't responded to earlier treatments or came back. It aims to help prevent the cancer from returning.
This trial tests CPX-351 together with ivosidenib in people with IDH1-mutated acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS). It aims to improve disease control, especially in tumors with a specific genetic change called IDH1.
This study tests a mix of medicines (cladribine, low-dose cytarabine, and venetoclax) alternated with azacitidine and venetoclax to treat higher-risk CMML or MDS after prior treatment or when standard treatment may not work well. It may help by improving blood counts and controlling the disease.
This trial tests a combination treatment (chemo drugs plus a growth-factor medicine) for people newly diagnosed with acute myeloid leukemia (AML) or certain high-risk myelodysplastic syndromes (MDS). It may help by targeting cancer cells in the blood and bone marrow and improving remission chances.
This Phase 2 trial compares treatment approaches for people with higher-risk MDS or a specific type of AML before they get a stem cell transplant. The goal is to see which approach helps you get ready for transplant more safely and effectively.
Hear when a new Blasts More Than 5 Percent of Bone Marrow Nucleated Cells trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.